Advancing rheumatology research: UCB at ACR Convergence 2024

The American College of Rheumatology (ACR) Convergence is a highly anticipated event in the calendar year, bringing together medical experts and pharmaceutical industry professionals who share our commitment to improving patient outcomes in rheumatology. This year, ACR Convergence 2024 promises to be a dynamic platform with presentations on the latest innovations and discussions on emerging topics and trends. UCB will be showcasing our commitment to addressing the treatment gaps and delivering pioneering therapeutic options to those living with rheumatic diseases.

UCB will present new long-term data on managing rheumatic diseases, specifically in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). We are also proud to share new data in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). These data demonstrate meaningful improvements in clinical and patient-reported outcomes, showcasing the potential impact that innovative solutions can have on patient care and long-term health outcomes. Through our scientific expertise, patient-centric mindset, and diverse partnerships we aim to elevate care for people living with rheumatic diseases, supporting them in living as free as possible from challenges and uncertainty.

We cannot achieve this alone. By fostering collaborations with our partners and patients, we can draw on real-world experience and insights to guide our efforts in shaping the future of rheumatology.

Earlier this year, we captured conversations with UCB colleagues and industry experts, emphasizing the importance of collaboration in driving progress in rheumatology. These discussions reinforced our shared commitment to innovative, patient-centered care to reduce the treatment gap in conditions like PsA, axSpA and SLE. 

Watch below to learn more.